(See the Editorial Commentary by Kaasch and Jung on pages 29-30.)
community and healthcare settings, accounting for 20% of all healthcare-associated bacteremias [1, 2] . The mortality attributed to S. aureus bacteremia (SAB) and sepsis ranges from 20% to 30%. Mortality in S. aureus infective endocarditis (IE) is even higher and ranges from 19% to 65% [3] [4] [5] . In a large prospective study of SAB, 34% of cases developed 1 or more metastatic infections involving joints, kidneys, brain, bones, liver, spleen, or spine [6] . Therefore, timely diagnosis of IE in patients with SAB is critical as it has important implications regarding choice of antibiotic therapy, duration of treatment, and need for surgical intervention in patients with complicated IE.
Endocarditis may be either the primary source of SAB or a secondary metastatic complication resulting from hematogenous seeding of cardiac valves from an extracardiac infectious focus. Clinical manifestations of S. aureus IE are nonspecific [7] , and classic stigmata of IE are typically absent early in the course of infection. Transesophageal echocardiogram (TEE) is considered the imaging test of choice as it is superior to transthoracic echocardiogram (TTE) to evaluate for IE in adults, especially in the setting of prosthetic heart valves and implanted cardiac devices [8] [9] [10] [11] [12] [13] . However, the evidence that TEE should be performed in every patient with SAB is limited [8, 14, 15] . TEE is an expensive and invasive test, is not readily available in all medical centers, and is performed in a fraction of patients with SAB in the usual course of patient care [16, 17] .
The usefulness of TEE in SAB patients depends on the pretest probability of IE. The prevalence of IE among patients with SAB varies depending on the study population. While earlier investigations reported a wide range (5%-64%) of IE among SAB patients, more recent studies have reported 5%-17% prevalence [6, [18] [19] [20] [21] [22] . Therefore, while TEE is appropriate in patients with high likelihood of IE, it is probably not necessary for every patient with SAB. Recently, simple criteria to guide use of echocardiography were proposed [23] [24] [25] . However, a minority of patients in these studies underwent TEE. Our aim in this study was to develop a simple and easy-to-use clinical scoring system to guide use of TEE in the management of both communityand healthcare-associated SAB cases.
METHODS

Study Overview
All adults (age ≥18 years) hospitalized at our institution with SAB from July 2006 to June 2011 were included in the study. Cases of SAB were identified in the Department of Laboratory Medicine and Microbiology database. Demographic, microbiologic, echocardiographic, and follow-up (at least 12 weeks) data were collected. Patients who did not undergo TEE and for whom follow-up data at 12 weeks were unavailable were excluded from the analysis (Figure 1 ). Patients who did not undergo TEE but had 12-week follow-up were included. Patients who died or chose palliative care/hospice prior to diagnostic evaluation for IE were also excluded. Electronic medical records were reviewed to collect follow-up data for 12 weeks or longer. The Mayo Foundation Institutional Review Board approved the study.
Definitions
Cases of SAB were classified as nosocomial, healthcare associated, or community acquired, as defined by Friedman et al [26] . Nosocomial bacteremia was defined as positive blood culture result first obtained from patients who had been hospitalized for ≥48 hours. Healthcare-associated bacteremia was defined as a positive blood culture result obtained from a patient at the time of hospital admission or within 48 hours of admission if the patient (a) received intravenous therapy at home, received wound care or specialized nursing care through a healthcare agency, or had intravenous medical therapy in the previous 30 days; patients whose only home therapy was oxygen use were excluded; (b) attended a hospital or hemodialysis clinic or received intravenous chemotherapy in the previous 30 days; (c) was hospitalized in an acute care hospital for 2 days in the previous 90 days; or (d) resided in a nursing home or long-term care facility. Community-acquired bacteremia was defined as a positive blood culture result obtained at the time of hospital admission or within 48 hours after hospital admission. Prolonged bacteremia was defined as persistently positive blood cultures for ≥72 hours. IE was defined by modified Duke criteria [27] . Echocardiographic evidence of IE was defined as presence of an oscillating intracardiac mass, myocardial abscess, new valvular regurgitation, or new dehiscence of a prosthetic valve. Only patients who met the modified Duke criteria for definite endocarditis were included.
Statistical Methods
Model Derivation
Descriptive statistics on study variables are presented as median (range or interquartile range), mean (standard deviation [SD]), or frequency count ( percentage), as appropriate. The associations between candidate risk factors and IE were measured using logistic regression and summarized with odds ratios and 95% confidence intervals. Each factor was screened for an association with IE via univariate logistic regression; those with an alpha level of 0.1 or less were carried forward in multivariable analyses. The multivariable logistic model was reduced to the most important risk factors using stepwise variable selection with backward elimination (alpha level of 0.05). Two-way interactions between candidate risk factors were also tested for importance. The day 1 scoring model was derived based on the modeling steps listed above using baseline risk factors available at the time of diagnosis. Excluding a small minority of patients who were lost to short-term follow-up, the algorithm was then repeated to derive a second scoring system, day 5, that incorporated "prolonged bacteremia."
Model Validation
We internally validated the fit and performance of both final models using the bootstrap method with 400 resamples. In a given resample, a new set of patients is randomly sampled (with replacement) from the original set, on whom a new model is fit using the same stepwise criteria. The model derived on each bootstrap resample was then tested on the original set of patients, as the difference in performance (eg, c-statistic) between this bootstrap and the test model provides a sense of overfitting in the original model selection. For both final models, we estimated the bias due to overfitting, or "optimism," and recalculated the c-statistic correcting for this bias. A detailed description of this statistical methodology is provided in the Supplementary Material.
Risk Stratification
From the final models, regression coefficients were used to derive the 2 separate risk scores for predicting IE. In particular, points were assigned for each risk factor in the model and weighted approximately by the respective regression coefficients. For optimal scoring, regression coefficients were rescaled by first dividing by the minimum absolute value among all coefficients and then multiplying each rescaled coefficient by a constant (such as 2 or 3, choosing the one producing the most optimal weighting scheme), and finally rounding the rescaled values to the nearest integer. Using these point values, a patient's risk score was simply computed as the aggregate number of points from his or her risk factor profile.
RESULTS
Study Population
A total of 757 patients with SAB were hospitalized at Mayo Clinic Rochester from July 2006 to June 2011. Thirty-one patients were excluded as they had declined research authorization; 48 patients were excluded due to insufficient data ( Figure 1) ; 39 patients died during the follow-up period before evidence of IE could be established; 9 patients did not undergo TEE and were lost to follow-up; and 678 individuals with SAB (24% community onset, 56% healthcare associated, and 20% nosocomial) who met the study criteria were included in the final analysis. Baseline characteristics are summarized in Table 1 . The majority of patients were male (65%) and mean age (SD) was 64.8 (5.7) years. Twelve percent of the patients had a cardiovascular implantable electronic device (CIED). Of these, 7% were permanent pacemakers (PPMs) and 5% were implantable cardioverter defibrillators (ICDs). Only 6% of patients had a prosthetic heart valve. Thirty-nine percent of the S. aureus isolates were methicillin resistant. Overall, 71% of the patients underwent TEE within 12 weeks of SAB diagnosis. In 68% of patients, TEE was performed within 14 days after first blood culture. A total of 85 patients (13%) fulfilled the modified Duke criteria for definite IE, of whom 56 (66%) had native valve endocarditis, 13 (15%) had prosthetic valve IE, and 25 (29%) had endocarditis related to a CIED. These included 8 (9%) patients with ICD-related IE and 17 (20%) with PPM-related IE. The proportion of patients with IE was 22% in community-acquired SAB, 11% in community-acquired healthcare-associated SAB, and 7% in nosocomial SAB. The proportion with IE was 18% in patients with hemodialysis, 30% in patients with prosthetic heart valves, 41% in patients with PPMs, 29% in patients with ICDs, and 21% in those with prolonged bacteremia lasting longer than 72 hours.
Model Derivation
Two scoring systems were derived for the clinical purpose of risk stratification at 2 time points: day 1 score (SAB diagnosis day) and day 5 score. Among the baseline factors identified from univariable screening and carried forward into multivariable modeling, the following were selected in the original model fit and corresponded to increased risk of IE: onset of SAB, CIED, prior intravenous drug abuse (IVDA), recent S. aureus infection, and absence of a skin or surgical site as a source of infection (Table 1) . However, based on internal validation of the model fit via bootstrap resampling, only onset of SAB and CIED were deemed robust predictors of IE. To derive the day 5 model, the effect of prolonged bacteremia, along with baseline variables, was assessed for 662 patients with SAB (7 patients who died within 5 days of an SAB diagnosis and 9 patients who lacked a negative culture were excluded). Prolonged bacteremia was found to be predictive of IE in the original sample and was internally validated as a predictor after being selected in 100% of the bootstrap models. The final day 5 model therefore included onset of SAB, presence of CIED, and prolonged bacteremia.
Risk Stratification
On the basis of final day 1 and day 5 models, regression coefficients were used to derive 2 risk scores for predicting IE in patients hospitalized for SAB. Points were assigned for each risk factor, weighted in magnitude by the corresponding regression coefficients, and summed together to define an individual's risk score (Table 2) .
DISCUSSION
There is limited evidence regarding optimal use of TEE in patients with SAB to evaluate for underlying IE (Table 4) . While some studies have suggested that TEE is dispensable in patients with uncomplicated SAB [23] [24] [25] , these studies focused on nosocomial SAB and <30% of cohorts had TEE performed, increasing the risk of verification bias. Considering that patients with sustained bacteremia (>72 hours) in these studies received prolonged (3-4 weeks) courses of antimicrobial therapy, it is conceivable that some patients with endocarditis were cured without an IE diagnosis being secured. The current investigation is one of the largest studies to assess the role of TEE in patients with SAB in which the majority (68% underwent TEE within 14 days, 71% underwent TEE within 12 weeks) of patients underwent TEE, decreasing the risk of verification bias and therefore a low likelihood of missing IE. Based on the results of the multivariable analysis, we propose 2 scoring systems to predict the risk of IE and, thus, the need for TEE on SAB diagnosis day (day 1) and when prolonged bacteremia is documented (day 5).
In the multivariable analysis, community-acquired SAB, presence of CIED or prosthetic heart valve, and prolonged bacteremia were independently associated with IE in patients with SAB. This is congruent with earlier publications aimed at identifying risk factors of complicated SAB [15, 19, [30] [31] [32] [33] [34] [35] . For the day 1 risk score (range, 0-5), screening individuals with a score of 2 or Figure 2 . A hypothetical application of 2-stage screening strategy on our study cohort. *Day 5 score was applied only on 620 patients in this hypothetical scenario. Fourteen patients either died or did not have follow up blood cultures. Abbreviation: SAB, Staphylococcus aureus bacteremia.
higher was the optimal threshold in terms of both sensitivity and specificity (65% and 70%, respectively). Choosing a higher cutoff value to target high-risk patients would improve specificity but at the expense of reduced sensitivity. For example, a screening cutoff of ≥4 would have selected 44 patients for TEE and correctly excluded a very high proportion of those without IE (specificity, 96%), while yielding only a small percentage of IE cases (sensitivity, 21%). Using the day 5 score (range 0-7) to inform an independent screening decision (assuming low-risk patients are not screened for IE based on the day 1 risk score), a cutpoint of ROC (receiver-operating characteristic curve) ≥3 had optimal diagnostic power based jointly on sensitivity and specificity (87% Figure 3 . Proposed algorithm for optimal use of transesophageal echocardiogram (TEE) in patients with Staphylococcus aureus bacteremia (SAB). *Intracardiac prosthesis: Implantable cardioverter-defibrillator, permanent pacemaker, prosthetic heart valve. Abbreviations: AHA, American Heart Association; CIED, cardiovascular implantable electronic device; IE, infective endocarditis; IDSA, Infectious Diseases Society of America. and 59%, respectively) with equal weight. Opting for a risk score more preferential to sensitivity, such as a score ≥2, would ensure that a higher proportion of all IE cases (sensitivity, 94%) are identified, although with a trade-off cost of increased TEE screening (specificity, 41%).
We propose a 2-stage screening strategy that combines the predictive values of day 1 and day 5 risk scores. The first stage (day 1 risk score) should be used to identify patients at highest risk of IE. Patients who have a high risk score on day 1 screening, such as ≥4, should undergo TEE soon after SAB is diagnosed as early detection of IE in high-risk patients may have therapeutic implications such as choice of antibiotic therapy (combination therapy if prosthetic valve IE is present) and need for surgical intervention (if indications for surgery, such as myocardial abscess, valve perforation, infected CIED, are present). This high-risk group includes patients with underlying implantable cardiac devices who develop community-onset SAB. If the initial TEE is negative for evidence of IE in this high-risk group, then they should be reevaluated with repeat TEE if bacteremia is prolonged. Repeat TEE was performed in 88 patients in our study cohort. In 5 patients whose initial TEE was negative, repeat TEE showed evidence of endocarditis. Patients with low risk score (eg, <4) on day 1 should be reassessed on day 5. For day 5 risk score, we favor a cutoff with very high negative predictive value, given the high mortality rate associated with IE, and defer TEE only in those with a very low likelihood of IE. For day 5, we suggest a risk score cutoff of <2 as it had a sensitivity of 98.8% and negative predictive value of 98.5%. Patients with either community-acquired SAB or prolonged bacteremia (≥72 hours) or those with underlying CIED will have day 5 scores ≥2 and should be evaluated with TEE. Although a significant risk factor in the modeling, prosthetic heart valve did not meet the more stringent criteria for inclusion in the scoring tool; this is possibly due to the small number of patients with prosthetic heart valves in our study cohort (6%). However, 2 of the 5 IE cases deemed as low risk by the scoring system had a prosthetic valve in place. Therefore, we have added patients with prosthetic heart valves to the high-risk category in our proposed decision-making algorithm (Figure 3) .
Strict application of the proposed scoring system to guide TEE use would have resulted in missing 5 IE cases in our SAB study cohort. Therefore, clinicians should not be discouraged from obtaining TEE if there is a strong clinical suspicion of IE in a given case, even if a patient does not meet scoring criteria. Table 5 includes the clinical characteristics of these 5 patients. As described above, 2 of the 5 patients had an underlying prosthetic heart valve, and we have added prosthetic valve to the high-risk category in our proposed algorithm. Moreover, all patients should have close clinical follow-up for at least 12 weeks to detect relapse or metastatic complications. In patients with recurrence or relapse of SAB, TEE should be done, regardless of initial clinical risk scoring and prior echocardiographic findings. Based on our classification scheme (Figures 2 and 3) , more than one-third of SAB patients could be managed without performing TEE.
In our study, 131 patients underwent both TTE and TEE within 14 days after first positive blood culture, of whom 41 patients were diagnosed with IE. TEE was positive in 85% of IE (35/41) and TTE was positive in only 34% (14/41). These data are consistent with data from several earlier studies that suggest the sensitivity of TEE is much higher than that of TTE. TEE is the imaging modality of choice to evaluate for IE in patients with SAB. Our study has several limitations, primarily due to its retrospective design. The decision to obtain TEE and its timing was at the discretion of the attending physician, and the median time to perform TEE was 4 days from the date of first positive blood culture. Therefore, it can be argued that some patients who underwent testing within 48 hours of SAB diagnosis but had prolonged bacteremia may have had a false-negative result for IE because testing at this stage may have missed evolving endocarditis. However, lack of relapse of SAB during the 12-week follow-up period suggests that these were likely true negative results. Because our cohort included few patients with IVDA as a risk factor for IE, our findings may not be applicable to this subset of higher-risk patients. The median duration of antibiotic therapy in those without IE was 28 days. The longer duration of antibiotics in non-IE patients is likely due to a higher complexity of cases in our tertiary referral center. It is possible that some patients with IE were undiagnosed but received longer antibiotic course. However, 71% of patients underwent TEE, hence the likelihood of unrecognized but treated IE is low. Also, due to variable duration of antimicrobial therapy in low-risk patients in our study cohort, it is unclear if a shorter course (2 weeks) of antimicrobial therapy is adequate, especially if an echocardiogram is deferred. Prospective studies are needed to further validate the scoring system and to address the question of antibiotic duration.
Overall, our study findings suggest that the risk of IE in individuals with SAB can be estimated using a simple scoring system that utilizes 2 elements of clinical history (onset of SAB and presence of CIED) and duration of bacteremia. We propose a 2-stage screening strategy to be applied on the day of SAB diagnosis (day1) and when results of day 3 blood cultures are available (day 5) to help guide the optimal use of TEE.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online (http://cid.oxfordjournals.org). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.
Notes
Financial support. This study was supported by a research grant from the American Heart Association (12CRP12080058) to M. R. S. ( principal investigator). Resources of the Mayo Clinic Center for Clinical and Translational Science, funded by the National Institutes of Health (Clinical and Translational Science Awards, UL1 RR024150), were used for data analysis and manuscript preparation. The study database was created and maintained using REDCap (grant UL1 TR000135).
Financial Disclosures. All <$10 000 unless specified otherwise. L. M. B. reports royalty payments (authorship) from UpToDate, Inc. (<$20 000) and editor-in-chief payments from the Massachusetts Medical Society (Journal Watch Infectious Diseases; <$20 000). M. R. S. reports receiving funds from TYRX Inc. and Medtronic for prior research unrelated to this study, administered according to a sponsored research agreement between Mayo Clinic and the study sponsor that prospectively defined the scope of the research effort and corresponding budget, and honoraria/consulting fees from Medtronic and Spectranetics.
Potential conflicts of interest. All authors: No potential conflicts of interest.
